Epilepsy Therapeutic Market Report 2024 (Global Edition)

Global Epilepsy Therapeutic Market Report 2024 Market Size Split by Type (First Generation, Second Generation, Third Generation), by Seizure (Generalized Seizures, Focal seizures, Both), by Distributi...

Epilepsy Therapeutic Market Report Description

We have various report editions of Epilepsy Therapeutic Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Epilepsy Therapeutic Market Insights Video

Competitive Landscape of the Epilepsy Therapeutic Market

The landscape of therapeutic epilepsy markets has long been competitive, Pfizer Inc., UCB SA and GlaxoSmithKline plc among the key players. Those companies concentrate on R&D projects that yield innovative medicines and treatment methods for epilepsy putting them ahead in this market and meeting an unfulfilled need by patients with epilepsy.

In Jan 2023, Zydus Lifesciences in India launched the generic Topiramate extended-release capsules in the U.S. This launch is expected to increase the number of AED choices available to patients aged six and older with partial onset and primary generalized tonic-clonic seizures . Such activities by participants are expected to drive the market expansion.

(Source:https://www.business-standard.com/article/news-cm/zydus-launches-topiramate-extended-release-capsules-123010600475_1.html)

Top Companies Market Share in Epilepsy Therapeutic Industry: (In no particular order of Rank)

• UCB Pharma S.A.
• GlaxoSmithKline Plc
• Sanofi
• SK Biopharmaceuticals
• Eisai Co.
• Ltd.
• Novartis AG
• Novel Laboratories Inc.
• Pfizer Inc.
• Neurelis
• Inc.
• Bausch Health Companies Inc.
• Dr. Reddy's Laboratories
• SUMITOMO PHARMA
• Jazz Pharmaceuticals
• Inc.
• Sun Pharmaceutical Industries Ltd.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Epilepsy Therapeutic Market

Which Region Dominates the Epilepsy Therapeutic Market in 2024?

According to Cognitive Market Research, in the year 2024, North America was the most prospering territory in the market of epilepsy therapy. This good fortune, all things considered, arises for several reasons including systems that are well established in healthcare high incidence rates of epilepsy and full-bodied research & development operations. Favorable reimbursement policies in addition to the mounting concern over epilepsy go some way to boosting this territory's market growth. This combined with comprehensive diagnostic and treatment facilities as well as one-stop shopping places for all major therapies makes North America the top market in the world for epilepsy drugs.

Which Region is Expanding at the Fastest CAGR?

In the epilepsy therapeutic market, the Asia Pacific region is growing the fastest Compound Annual Growth Rate (CAGR). The factors driving this trend include an increasingly epileptics-aware society, more money being spent on healthcare as well as improved infrastructures for healthcare in countries such as China or India. Market expansion in availing of new treatment options for patients and government efforts to combat neurology disorder both further this trend. Together with the presence of virgin territory yet untouched by marketing, as well as emerging economies with more money in the consumers' pockets, these all work to squeeze more growth out of epileptic treatment markets within Asia-Pacific.

The current report Scope analyzes Epilepsy Therapeutic Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Epilepsy Therapeutic

According to Cognitive Market Research, the global epilepsy therapeutic market size was estimated at USD 11258.2 Million out of which North America held the major market of around 40% of the global revenue with a market size of USD 4503.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Epilepsy therapeutic market with a market size of USD 3553.09 million in 2024 and is projected to grow at a CAGR of 3.0 % during the forecast period. The generalized market growth factors in the US include robust healthcare infrastructure, increasing prevalence of epilepsy, and ongoing research and development efforts.
• The Canada Epilepsy therapeutic market had a market share of USD 540.39 million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. In Canada, generalized market growth factors include government initiatives promoting epilepsy awareness, improving access to healthcare, and advancements in treatment options.
• The Mexico epilepsy therapeutic market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD 409.80 million in 2024.

Europe Epilepsy Therapeutic

According to Cognitive Market Research, the global epilepsy therapeutic market size was estimated at USD 11258.2 Million out of which Europe held the major market of around 30% of the global revenue with a market size of USD 3377.46 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.5% from 2024 to 2031.

• The United Kingdom's epilepsy therapeutic market had a market share of USD 567.41 million in 2024 and is projected to grow at a CAGR of 4.3% during the forecast period. Generalized market growth factors in the UK comprise a well-established healthcare system, rising public awareness about epilepsy, and investments in neurological research.
• The France epilepsy therapeutic market is projected to witness growth at a CAGR of 2.7% during the forecast period with a market size of USD 310.73 million in 2024.
• According to Cognitive Market Research, the German epilepsy therapeutic market size was valued at USD 668.74 million in 2024 and is projected to grow at a CAGR of 3.7% during the forecast period. In Germany, generalized market growth factors encompass technological advancements in epilepsy treatment, supportive government policies, and a growing patient population.
• The Italy epilepsy therapeutic market is projected to witness growth at a CAGR of 2.9% during the forecast period with a market size of USD 290.46 million in 2024.
• The Russia epilepsy therapeutic market is projected to witness growth at a CAGR of 2.5% during the forecast period with a market size of USD 523.51 million in 2024.
• The Spain epilepsy therapeutic market is projected to witness growth at a CAGR of 2.6% during the forecast period with a market size of USD 276.95 million in 2024.
• The Luxembourg epilepsy therapeutic market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD 104.70 million in 2024.
• The Portugal epilepsy therapeutic market is projected to witness growth at a CAGR of 3.3% during the forecast period with a market size of USD 70.93 million in 2024.
• The Greece epilepsy therapeutic market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD 40.53 million in 2024.
• The Rest of Europe epilepsy therapeutic market is projected to witness growth at a CAGR of 2.2% during the forecast period with a market size of USD 523.51 million in 2024.

Asia Pacific Epilepsy Therapeutic Market

According to Cognitive Market Research, the global epilepsy therapeutic market size was estimated at USD 11258.2 Million out of which Asia Pacific held the major market of around 23% of the global revenue with a market size of USD 2589.39 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Epilepsy therapeutic market size was valued at USD 1165.22 million in 2024 and is projected to grow at a CAGR of 6.5% during the forecast period. Generalized market growth factors in China involve increasing healthcare expenditure, improving healthcare infrastructure, and rising awareness about epilepsy management.
• The Japan epilepsy therapeutic market is projected to witness growth at a CAGR of 5.5% during the forecast period with a market size of USD 357.34 million in 2024.
• The India Epilepsy therapeutic market had a market share of USD 310.73 million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period. In India, generalized market growth factors include a large patient population, expanding healthcare access, and investments in research and development of epilepsy treatments.
• The South Korea epilepsy therapeutic market is projected to witness growth at a CAGR of 6.1% during the forecast period with a market size of USD 258.94 million in 2024.
• The Australia epilepsy therapeutic market is projected to witness growth at a CAGR of 6.7% during the forecast period with a market size of USD 134.65 million in 2024.
• The South East Asia epilepsy therapeutic market is projected to witness growth at a CAGR of 8.0% during the forecast period with a market size of USD 178.67 million in 2024.
• The Rest of APAC epilepsy therapeutic market is projected to witness growth at a CAGR of 6.8% during the forecast period with a market size of USD 183.85 million in 2024.

South America Epilepsy Therapeutic Market

According to Cognitive Market Research, the global epilepsy therapeutic market size was estimated at USD 11258.2 Million out of which Latin America held the major market of around 5% of the global revenue with a market size of USD 562.91 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil epilepsy therapeutic market size was valued at USD 240.93 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. Generalized market growth factors in Brazil entail improving healthcare infrastructure, rising epilepsy awareness initiatives, and investments in neurology research.
• The Argentina epilepsy therapeutic market had a market share of USD 94.57 million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period. In Argentina, generalized market growth factors encompass government initiatives to improve epilepsy care, increasing access to healthcare services, and advancements in treatment modalities.
• The Colombia epilepsy therapeutic market is projected to witness growth at a CAGR of 4.2% during the forecast period with a market size of USD 50.10 million in 2024.
• The Peru epilepsy therapeutic market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD 46.16 million in 2024.
• The Chile epilepsy therapeutic market is projected to witness growth at a CAGR of 4.7% during the forecast period with a market size of USD 40.53 million in 2024.
• The Rest of LATAM epilepsy therapeutic market is projected to witness growth at a CAGR of 3.5% during the forecast period with a market size of USD 90.63 million in 2024.

Middle East and Africa Epilepsy Therapeutic Market

According to Cognitive Market Research, the global epilepsy therapeutic market size was estimated at USD 11258.2 Million out of which MEA held the major market of around 2.00% of the global revenue with a market size of USD 225.16 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.

• The GCC Countries Epilepsy therapeutic market is projected to witness growth at a CAGR of 5.5% during the forecast period with a market size of USD 96.37 million in 2024. Generalized market growth factors in the GCC region include healthcare infrastructure development, rising prevalence of epilepsy, and government initiatives to enhance neurological care.
• The Egypt epilepsy therapeutic market is projected to witness growth at a CAGR of 5.0% during the forecast period with a market size of USD 23.64 million in 2024.
• The South African epilepsy therapeutic market is projected to witness growth at a CAGR of 5.7% during the forecast period with a market size of USD 35.58 million in 2024. Generalized market growth factors in South Africa involve increasing healthcare investments, rising epilepsy awareness campaigns, and advancements in diagnostic and treatment facilities.
• The Turkey epilepsy therapeutic market is projected to witness growth at a CAGR of 4.2% during the forecast period with a market size of USD 19.36 million in 2024. The Nigeria epilepsy therapeutic market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD 23.64 million in 2024.
• The Rest of MEA epilepsy therapeutic market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD 26.57 million in 2024.

Epilepsy Therapeutic Market Analysis

Epilepsy Therapeutic Market Type Segment Analysis

According to Cognitive Market Research, the current rising star of the epilepsy therapeutic market is the second-generation segment. The advent of drugs like levetiracetam and lamotrigine has ensured that second-generation antiepileptic medicines are very well received because they are more effective and less toxic than any previously generation broad wave patients can as well bring into play its compelling market position. This segment can benefit from extensive clinical experience strong confidence of physicians.

It is the market of epilepsy therapy's fast moving product section. Third-generation AEDs offer hope to patients with drug-resistant epilepsy. They possess innovative drugs and novel mechanisms of action that promise better lives for bad patients. With substantial vested interest and international drug regulatory approvals now coming (and foreseen in the future), third-generation AEDs are expected to grow impressively in the next two years. They will be a major derivative source for the market this year.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Epilepsy Therapeutic Industry. Request a Free Sample PDF!

Epilepsy Therapeutic Market Seizure Type Segment Analysis

According to Cognitive Market Research, In the market of epilepsy therapeutic, the main segment today is that of Generalized Seizures. These involve entire-brain seizures with loss of consciousness as the usual result. Generalized seizures comprise a major share of epilepsy cases around the world, promoting a market for medication aimed at this type of seizure. Pharmaceutical firms have developed various antiepileptic drugs especially for use in generalized seizures. As a result, this segment reigns supreme in the epilepsy therapeutic market. It is precisely this sort of standardized treatment protocol for generalized seizures which have secured the established state of this segment within the market under review.

The fastest growing segment in the Epilepsy Therapeutic Market is Focal Seizures. These begin in one part of the brain only and may provoke changes in thoughts or emotions without unconsciousness. As diagnosis methods become more and more advanced, causing widespread recognition among physicians of focal seizures, so the demand for drugs that target specifically this type of seizure is rising meteorically. Pharmaceutical companies are working to develop new drugs and forms of therapy designed for the particular characteristics of focal seizures, driving this segment's growth within today's epilepsy therapeutic market.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Epilepsy Therapeutic Distribution Segment Analysis

According to Cognitive Market Research, Hospital pharmacies are the leader in the distribution channel outlook of epilepsy therapeutic market. Possessing a wide distribution network and offering all manner of drugs to inpatients or outpatients both, they can satisfy everybody's needs for medicine. Draw from the trust placed by patients in hospital-based healthcare and provide convenience of prescription dispensing during hospital visits. Using hospital pharmacies, you might be prescribed antiepileptic drugs not found just anywhere, it really makes their position atop the heap of markets that much firmer.

Online pharmacies represent the fastest-growing segment in the distribution channel outlook. Factors contributing to its growth include increasing internet penetration, convenience of drug procurement and the trend towards telemedicine. Online pharmacies allow for prescription orders from home, especially important in the Covid-19 era. They can often be purchased at competitive prices and delivered to your door, thus furthering the convenience and economy that more and more people are seeking in their epilepsy treatment programs.

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Epilepsy Therapeutic Service Provider Segment Analysis

According to Cognitive Market Research, In the Service Provider Outlook, hospitals are the leading segment in the Epilepsy Therapeutic Market. They offer comprehensive epilepsy care, ranging from diagnosis to treatment and long-term management. This one-stop service draws patients looking for specialized neurological care. Equipped with modern facilities, a multi-disciplinary team comprising neurologists, a neurosurgeon and others, plus access to advanced diagnostic equipment and modalities of treatment; hospital share in the epilepsy therapeutic market is heavy. Their ability to offer a wide range of services all under one roof and meet the needs of different patients in this area leads to their dominance over others.

Ambulatory Surgical Centers (ASCs) are the fastest-growing segment in the Service Provider Outlook. They perform epilepsy surgical operations including resective surgery and neurostimulation treatments on a single patient-in a day care setting. With the development of minimally invasive techniques and technologies, ASCs have become an efficient, cost-effective alternative to traditional hospital surgery. The popularity of day-surgery procedures, less time spent in the hospital and lower costs are behind rapid growth for ASCs in the epilepsy therapeutic market. Their services are inline with today's living standards.

• Hospitals
• Ambulatory Surgical Centers
• Diagnostic Centers
• Specialty clinics

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion